Marksans Pharma Limited

NSE MARKSANS.NS

Marksans Pharma Limited EPS (Diluted) for the year ending March 31, 2024: USD 0.08

Marksans Pharma Limited EPS (Diluted) is USD 0.08 for the year ending March 31, 2024, a 6.38% change year over year. EPS (Diluted) reflects the company's earnings per share adjusted for the potential dilution that could occur if all convertible securities were converted to common stock, providing a more conservative profitability measure.

Marksans Pharma Limited EPS (Diluted) for the year ending March 31, 2023 was USD 0.08, a 31.30% change year over year.
Marksans Pharma Limited EPS (Diluted) for the year ending March 31, 2022 was USD 0.06, a -24.49% change year over year.
Marksans Pharma Limited EPS (Diluted) for the year ending March 31, 2021 was USD 0.08, a 107.27% change year over year.
Marksans Pharma Limited EPS (Diluted) for the year ending March 31, 2020 was USD 0.04, a 33.88% change year over year.

Key data

Date	EPS (Diluted)	Shares (Diluted, Weighted)	Shares (Basic, Weighted)	Revenue

NSE: MARKSANS.NS

Marksans Pharma Limited

CEO	Mr. Mark B. Saldanha
IPO Date	July 19, 2002
Location	India
Headquarters	Grandeur
Employees	1,141
Sector	Health Care
Industries Pharmaceuticals

Description

Marksans Pharma Limited, together with its subsidiaries, engages in the research and development, manufacturing, marketing, distribution, and sale of generic pharmaceutical formulations worldwide. The company offers products in the analgesics, benign prostatic hyperplasia, antidiabetic, epilepsy, anti-inflammatory, hyperparathyroidism, diabetes, antacids, neurology, cardiovascular, hormonal, oncology, gastroenterology, antidiabetic, pain management, gynecology, antibiotic, antifungal, antiulceratives, vitamins, dermatology, cephalosporins, injectables, anti-allergy, antibacterial, and hypertension therapeutic areas. It also provides contract research and manufacturing services. Marksans Pharma Limited was incorporated in 1992 and is headquartered in Mumbai, India.

Key trends

Past 5 years